Loading, Please Wait...
Results of new studies add to the growing body of data supporting the PKG as an important continuous, objective measure of movement for optimized management of Parkinson’s Disease
PORTSMOUTH, N.H. and LONDON and MELBOURNE, Australia, Sept. 20, 2019 (GLOBE NEWSWIRE) -- Global Kinetics Corporation Ltd. today announced that data from new clinical studies of its wearable, FDA-cleared Personal KinetiGraph® (PKG®) will be presented in ten poster presentations at the International Congress of Parkinson’s Disease and Movement Disorders (MDS). The Congress will be held September 22-26 in Nice, France.
John Schellhorn, CEO of Global Kinetics Corporation, said, “The posters that will be presented at MDS demonstrate the utility of the PKG in objectively assessing multiple dimensions of Parkinson’s disease. These include its use in more effectively managing Parkinson’s disease, assessing motor parameters of the disease, exploring the relationship between motor and non-motor fluctuations in Parkinson’s disease and evaluating the relationship between Parkinson’s disease and impulsive behaviour and sleep disturbances. The absence of continous objective assessments for Parkinson’s disease has been a barrier to optimizing the management and outcomes for patients living with this chronic, progressive condition. We are proud that the PKG is enabling more objective and data driven approaches to the care of patients with Parkinson’s disease and look forward to sharing these data with the Parkinson’s disease community at MDS.”
In addition to these presentations, Global Kinetics is proud to share they have now enrolled 137 patients into their U.S. APPRISE Randomized Controlled Trial.
About Global Kinetics Corporation Ltd.
Global Kinetics Corporation Ltd. is committed to improving the lives of those with Parkinson’s disease with advanced medical technologies. The company was formed in 2007 to commercialize its lead product, the Personal KinetiGraph (PKG). The PKG enables the precise monitoring, quantification, and reporting of movement symptoms in Parkinson’s. To date, Global Kinetics has supported clinical decisions for doctors who have treated more than 48,000 patients with Parkinson’s disease, generating more than 6,000,000 hours of clinical data from our FDA-cleared, CE-marked PKG wearable device. Global Kinetics, a privately held company, is headquartered in Melbourne, Australia with offices in London, UK, Minneapolis, MN, and Portsmouth, NH, USA.
For more information, visit: www.globalkineticscorporation.com
Follow our LinkedIn updates: https://www.linkedin.com/company/globalkineticscorp
Chantal Beaudry / Amy Feldman
+1 (646) 871-8480 / +1 (212) 867-1770